AI assistant
SYNTARA LIMITED — Share Issue/Capital Change 2017
Jan 24, 2017
65830_rns_2017-01-24_13414b9f-c1d1-40ed-a79e-d64afb70e968.pdf
Share Issue/Capital Change
Open in viewerOpens in your device viewer
Rule 2.7, 3.10.3, 3.10.4, 3.10.5
Appendix 3B
New issue announcement, application for quotation of additional securities and agreement
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.
Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13
Name of entity
Pharmaxis Ltd
ABN
75 082 811 630
We (the entity) give ASX the following information.
Part 1 - All issues
You must complete the relevant sections (attach sheets if there is not enough space).
1 +Class of +securities issued or to be issued
Fully paid ordinary shares
- 2 Number of +securities issued or to be issued (if known) or maximum number which may be issued
- 3 Principal terms of the +securities (e.g. if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)
400,000
Issue of fully paid ordinary shares upon exercise of options granted under the Pharmaxis Ltd Employee Option Plan.
+ See chapter 19 for defined terms.
| 4 | Do the +securitiesrank equallyin all respects from the +issuedate with an existing +classofquoted +securities?If the additional +securitiesdonot rank equally, please state:the date from which they dotheextenttowhichtheyparticipateforthenextdividend, (in the case of atrust,distribution)orinterest paymentthe extent to which they donot rank equally, other thaninrelationtothenextdividend,distributionorinterest payment | Yes |
|---|---|---|
| 5 | Issue price or consideration | 400,000 shares (PXSAAS): exercise price of$nil per share |
| 6 | Purpose of the issue(If issuedas consideration forthe acquisition of assets, clearlyidentify those assets) | ExerciseofoptionsunderPharmaxisLtdEmployee Option Plan |
| 6a | Is the entity an +eligibleentitythathasobtainedsecurityholder approval under rule 7.1A?If Yes, complete sections 6b – 6hin relation to the +securitiesthesubject of this Appendix 3B, andcomply with section 6i | No |
| 6b | Thedatethesecurityholderresolution under rule 7.1A waspassed | n/a |
| 6c | +securitiesNumberofissuedwithoutsecurityholderapproval under rule 7.1 | n/a |
+ See chapter 19 for defined terms.
- 6d Number of +securities issued with security holder approval under rule 7.1A
- 6e Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)
- 6f Number of +securities issued under an exception in rule 7.2
- 6g If +securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the +issue date and both values. Include the source of the VWAP calculation.
- 6h If +securities were issued under rule 7.1A for non‐cash consideration, state date on which valuation of consideration was released to ASX Market Announcements
- 6i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements
- 7 +Issue dates
Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.
Cross reference: item 33 of Appendix 3B.
n/a
n/a
n/a
n/a
n/a
n/a
25 January 2017
- See chapter 19 for defined terms.
| Number | +Class | ||
|---|---|---|---|
| 8 | +classNumberandofall+securitiesquotedonASX+securities(includingtheinsection 2 if applicable) | 319,106,844 | Fully paid ordinary shares |
| Number | +Class | ||
|---|---|---|---|
| 9 | +classNumberandofall | 15,000 | Optionsexpiring13 |
| +securitiesnot quoted on ASX | December2016withan | ||
| +securities(includingthein | exercisepriceof$2.9310 | ||
| section 2 if applicable) | (ASX Code PXSAF) | ||
| 102,500 | Optionsexpiring17June | ||
| 2017 with an exercise price | |||
| of$3.1755(ASXCode | |||
| PXSAH) | |||
| 17,000 | Options expiring 9 August | ||
| 2017 with an exercise price | |||
| of$3.2490(ASXCode | |||
| PXSAL) | |||
| 40,000 | Optionsexpiring5 | ||
| November2017withan | |||
| exercisepriceof$4.1500 | |||
| (ASX Code PXSAT) | |||
| 3,000 | Options expiring 7 February | ||
| 2018 with an exercise price | |||
| of$3.1266(ASXCode | |||
| 4,000 | PXSAN)Options expiring 10 April | ||
| 2018 with an exercise price | |||
| of$1.9735(ASXCode | |||
| PXSAP) | |||
| 1,500 | Optionsexpiring22June | ||
| 2018 with an exercise price | |||
| of$1.4590(ASXCode | |||
| PXSAR) | |||
| 100,500 | Options expiring 11 August | ||
| 2018 with an exercise price | |||
| of$1.6770(ASXCode | |||
| PXSAS) | |||
| 200,000 | Optionsexpiring22June | ||
| 2018 with an exercise price | |||
| of$1.4590(ASXCode | |||
| PXSAV) | |||
| 2,500 | Options expiring 22 October | ||
| 2018 with an exercise price | |||
| of$1.4660(ASXCode | |||
| PXSAAA) |
+ See chapter 19 for defined terms.
| Number | +Class |
|---|---|
| 5,000 | Optionsexpiring10 |
| December 2018 with an | |
| exercise price of $1.0207 | |
| (ASX Code PXSAAB) | |
| Options expiring 22 June | |
| 86,500 | 2019withanexercise |
| price of $2.4098 (ASX | |
| Code PXSAAE) | |
| 10,000 | Optionsexpiring6 |
| September 2020 with a | |
| zero exercise price (ASX | |
| Code PXSAAF) | |
| 202,000 | Options expiring 28 June |
| 2022 with a zero exercise | |
| price(ASXCode | |
| PXSAG) | |
| 30,000 | Optionsexpiring17 |
| October 2022 with a zero | |
| exercise price (ASX Code | |
| PXSAAO) | |
| 192,750 | Options expiring 6 June |
| 2023 with a zero exercise | |
| price(ASXCode | |
| PXSAAP) | |
| 9,313,000 | Performance Rights (ASX |
| Code PXSAAS) |
+ See chapter 19 for defined terms.
10 Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests) n/a
Part 2 - Pro rata issue
| 11 | Issecurityholderapprovalrequired? | |
|---|---|---|
| 12 | Is the issue renounceable or non‐renounceable? | |
| 13 | +securitiesRatioinwhichthewill be offered | |
| 14 | +Classof +securitiesto which theoffer relates | |
| 15 | +Recorddatetodetermineentitlements | |
| 16 | Willholdingsondifferentregisters(orsubregisters)beaggregatedforcalculatingentitlements? | |
| 17 | Policy for deciding entitlementsin relation to fractions | |
| 18 | Names of countries in which theentity has security holders whowillnotbesentnewofferdocumentsNote: Security holders must be told how theirentitlements are to be dealt with. | |
| Cross reference: rule 7.7. | ||
| 19 | Closingdateforreceiptofacceptances or renunciations | |
| 20 | Names of any underwriters |
+ See chapter 19 for defined terms.
| 21 | Amount of any underwriting feeor commission |
|---|---|
| 22 | Namesofanybrokerstotheissue |
| 23 | Feeorcommissionpayabletothe broker to the issue |
| 24 | Amountofanyhandlingfeepayabletobrokerswholodgeacceptances or renunciations onbehalf of security holders |
| 25 | Iftheissueiscontingentonsecurityholders'approval,thedate of the meeting |
| 26 | Date entitlement and acceptanceform and offer documents will besent to persons entitled |
| 27 | If the entity has issued options,andthetermsentitleoptionholderstoparticipateonexercise,thedateonwhichnoticeswillbesenttooptionholders |
| 28 | Date rights trading will begin (ifapplicable) |
| 29 | Date rights trading will end (ifapplicable) |
| 30 | Howdosecurityholdersselltheir entitlements in full througha broker? |
| 31 | How do security holders sell partof their entitlements through abrokerandacceptforthebalance? |
| 32 | How do security holders disposeof their entitlements (except bysale through a broker)? |
+ See chapter 19 for defined terms.
33 +Issue date
Part 3 - Quotation of securities
You need only complete this section if you are applying for quotation of securities
34 Type of +securities (tick one)
(a) Securities described in Part 1
(b) All other +securities
Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities
+ See chapter 19 for defined terms.
Entities that have ticked box 34(a)
Additional securities forming a new class of securities
Tick to indicate you are providing the information or documents
| 35 | If the +securities are +equity securities, the names of the 20 largest holders of theadditional +securities,and the number and percentage of additional +securitiesheld by those holders |
|---|---|
| 36 | If the +securities are +equity securities, a distribution schedule of the additional+securitiessetting out the number of holders in the categories1 ‐ 1,0001,001 ‐ 5,0005,001 ‐ 10,00010,001 ‐ 100,000100,001 and over |
| 37 | A copy of any trust deed for the additional +securities |
| Entities that have ticked box 34(b) | |
| 38 | Number of +securitiesfor which+quotationis sought |
| 39 | +Class+securitiesofforwhichquotation is sought |
| 40 | Do the +securitiesrank equally inall respects from the +issuedatewith an existing +classof quoted+securities? |
| +securitiesIftheadditionaldonot rank equally, please state:the date from which they dotheextenttowhichtheyparticipateforthenextdividend,(inthecaseofatrust, distribution) or interestpaymentthe extent to which they donot rank equally, other than inrelation to the next dividend,distributionorinterestpayment |
+ See chapter 19 for defined terms.
41 Reason for request for quotation now
Example: In the case of restricted securities, end of restriction period
(if issued upon conversion of another +security, clearly identify that other +security)
| Number | +Class | ||
|---|---|---|---|
| 42 | +classNumberandofall+securitiesquotedonASX+securities(includingtheinclause 38) |
+ See chapter 19 for defined terms.
Quotation agreement
- 1 +Quotation of our additional +securities is in ASX's absolute discretion. ASX may quote the +securities on any conditions it decides.
- 2 We warrant the following to ASX.
- The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
- There is no reason why those +securities should not be granted +quotation.
- An offer of the + securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.
Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty
- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no‐one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.
- If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.
- 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- 4 We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.
(Company secretary)
Sign here: .................................................... Date: 25 January 2017
Print name: David McGarvey
+ See chapter 19 for defined terms.